1. Home
  2. RAPP vs PHAR Comparison

RAPP vs PHAR Comparison

Compare RAPP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$27.16

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.21

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAPP
PHAR
Founded
2022
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
RAPP
PHAR
Price
$27.16
$16.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$47.00
$38.00
AVG Volume (30 Days)
337.3K
37.6K
Earning Date
03-10-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
N/A
$362,274,000.00
Revenue This Year
N/A
$25.19
Revenue Next Year
N/A
$4.47
P/E Ratio
N/A
$2,894.31
Revenue Growth
N/A
26.78
52 Week Low
$6.43
$7.50
52 Week High
$42.27
$21.34

Technical Indicators

Market Signals
Indicator
RAPP
PHAR
Relative Strength Index (RSI) 48.33 39.57
Support Level $25.21 $15.95
Resistance Level $28.59 $18.03
Average True Range (ATR) 1.53 0.76
MACD 0.01 -0.49
Stochastic Oscillator 52.96 7.05

Price Performance

Historical Comparison
RAPP
PHAR

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: